zhengguangmycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zhengguangmycin: antitumor antibiotic complex consisting of more than 10 components; produced by Streptomyces pingyangensis; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	56841895
MeSH ID	M0077080

Synonyms (6)

Synonym
77108-50-0
zhangguangmycin
zhengguangmycin
zhengguangmycin b2
zhengguangmycins
DTXSID80227899

Research Excerpts

Compound-Compound Interactions

Excerpt	Reference	Relevance
"To evaluate the effect of locoregional immunotherapy of interleukin 2 (IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas."	( [Effect of local immunotherapy of interleukin 2(IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas]. Hu, Q; Tang, E; Zhou, B, 2003)	0.32
"To compare the clinical efficacy and toxicity of teniposide (VM26) of higher dose with those of lower dose, both combined with cisplatin (CDDP) and pingyangmycin (PYM), in the treatment of patients with squamous cell carcinoma of oral and maxillofacial region (SCCOMR)."	( [Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma]. Chen, WT; Guo, W; Pan, HY; Qiu, WL; Xu, Q; Ye, DX, 2004)	0.32
" Thirty-three patients were treated with higher dose of VM26 (total dose was 320 mg) combined with CDDP and PYM (PTP1), the other thirty-two patients were treated with lower dose (total dose was 158 mg) of VM26 combined with CDDP and PYM (PTP2)."	( [Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma]. Chen, WT; Guo, W; Pan, HY; Qiu, WL; Xu, Q; Ye, DX, 2004)	0.32
"25% and relatively slighter adverse events could be obtained for lower dose of VM26 combined with CDDP and PYM (PTP2)."	( [Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma]. Chen, WT; Guo, W; Pan, HY; Qiu, WL; Xu, Q; Ye, DX, 2004)	0.32
"To observe the cytotoxicity of chymopapain combined with pingyangmycin (PYM) on mouse hepatoma cell line hapa-6 in vitro."	( [Cytotoxicity of chymopapain combined with pingyangmycin on mouse hepatoma cell line hepa-6]. Jiang, X; Jie, W; Taicheng, Y; Xiaoling, C; Yong, G, 2004)	0.32
" Cooperation effect was showed when three different concentration chymopapain combined with PYM during 48 hours."	( [Cytotoxicity of chymopapain combined with pingyangmycin on mouse hepatoma cell line hepa-6]. Jiang, X; Jie, W; Taicheng, Y; Xiaoling, C; Yong, G, 2004)	0.32
" Cooperation effect was showed when chymopapin was combined with PYM."	( [Cytotoxicity of chymopapain combined with pingyangmycin on mouse hepatoma cell line hepa-6]. Jiang, X; Jie, W; Taicheng, Y; Xiaoling, C; Yong, G, 2004)	0.32

Dosage Studied

Excerpt	Relevance	Reference
" As determined by a colony-forming assay, the dose-response curves obtained from cells exposed to PYM for 1 h were of one type only: biphasic exponential."	( [Anticancer spectrum of pingyangmycin in vitro]. Li, XT, 1990)	0.28

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (80)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	20 (25.00)	18.7374
1990's	25 (31.25)	18.2507
2000's	35 (43.75)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	10.01 (24.57)
Research Supply Index	4.44 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (10.01)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (5.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (1.25%)	4.05%
Observational	0 (0.00%)	0.25%
Other	75 (93.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.07	3	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	2	1	0	aziridines
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.01	1	0	mitomycin	alkylating agent; antineoplastic agent
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	2.38	2	0	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
ficusin Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.	1.98	1	0	psoralens	plant metabolite
ditiocarb Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.	1.98	1	0	dithiocarbamic acids	chelator; copper chelator
1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt Chymopapain: A cysteine endopeptidase isolated from papaya latex. Preferential cleavage at glutamic and aspartic acid residues. EC 3.4.22.6.	2.02	1	0	organosulfur compound; sulfonic acid derivative
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	2.01	1	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	2.4	2	0	manganese group element atom
tetrandrine tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity	1.97	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
at 1258 nitrocaphane: structure	1.96	1	0
methotrexate [no description available]	3.11	5	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
homoharringtonine Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.	1.99	1	0	alkaloid ester; enol ether; organic heteropentacyclic compound; tertiary alcohol	anticoronaviral agent; antineoplastic agent; apoptosis inducer; protein synthesis inhibitor
carboplatin [no description available]	2.02	1	0
bleomycin a6 bleomycin A6: forms conjugate with monoclonal antibody anti-CCT2 which binds to leukemia cells	1.97	1	0
arginine Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.	3.4	1	1
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.02	1	0
sodium morrhuate Sodium Morrhuate: The sodium salts of the fatty acids in cod liver oil; an irritant and sclerosing agent used to treat varicose veins and arthritic joints.	2.92	4	0

Condition	Relationship Strength	Studies	Trials
Carcinoma, Epidermoid [description not available]	7.02	30	3
Cancer of Mouth [description not available]	6.37	15	3
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	7.02	30	3
Mouth Neoplasms Tumors or cancer of the MOUTH.	6.37	15	3
Cancer of Lung [description not available]	2.9	4	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.9	4	0
Angioma, Cavernous A tumor-like mass with large vascular space that is filled with blood or lymph.	5	9	1
Orbital Neoplasms Neoplasms of the bony orbit and contents except the eyeball.	2	1	0
Facial Neoplasms New abnormal growth of tissue in the FACE.	3.23	6	0
Cancer of Jaw [description not available]	2.9	4	0
Cancer of Esophagus [description not available]	4.86	8	1
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	4.86	8	1
Cancer of Head [description not available]	2.9	4	0
Endothelioma, Lymphatic [description not available]	2.01	1	0
Cancer of the Tongue [description not available]	3.69	10	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.9	4	0
Lymphangioma A benign tumor resulting from a congenital malformation of the lymphatic system. Lymphangioendothelioma is a type of lymphangioma in which endothelial cells are the dominant component.	2.01	1	0
Tongue Neoplasms Tumors or cancer of the TONGUE.	3.69	10	0
Cancer of Cervix [description not available]	2.39	2	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.39	2	0
Cancer of Colon [description not available]	2.01	1	0
Hepatocellular Carcinoma [description not available]	2.9	4	0
Cancer of Liver [description not available]	2.9	4	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.01	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.9	4	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.9	4	0
Cancer of Nasopharynx [description not available]	2.67	3	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2.67	3	0
Recrudescence [description not available]	2.01	1	0
Angio-Osteohypertrophy Syndrome [description not available]	2.01	1	0
Maxillary Neoplasms Cancer or tumors of the MAXILLA or upper jaw.	2.38	2	0
Fibroid [description not available]	2.02	1	0
Cancer of the Uterus [description not available]	2.02	1	0
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	2.02	1	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	2.02	1	0
Cancer of Lip [description not available]	4.06	3	1
Anasarca [description not available]	2.02	1	0
Craniofacial Pain [description not available]	2.02	1	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.02	1	0
Facial Pain Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.	2.02	1	0
Experimental Hepatoma [description not available]	2.67	3	0
Alveolitis, Fibrosing [description not available]	2.9	4	0
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	2.9	4	0
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	2.88	4	0
Pterygium An abnormal triangular fold of membrane in the interpalpebral fissure, extending from the conjunctiva to the cornea, being immovably united to the cornea at its apex, firmly attached to the sclera throughout its middle portion, and merged with the conjunctiva at its base. (Dorland, 27th ed)	1.98	1	0
Adenocarcinoma, Basal Cell [description not available]	2.38	2	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.98	1	0
Experimental Mammary Neoplasms [description not available]	1.98	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.38	2	0
Abnormalities, Autosome [description not available]	2.38	2	0
Cancer of Larynx [description not available]	2.39	2	0
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	2.39	2	0
Breast Cancer [description not available]	2.39	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.39	2	0
Adenocystic Carcinoma [description not available]	2.67	3	0
Carcinoma, Adenoid Cystic Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)	2.67	3	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2	1	0
Angioma A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.	2	1	0
Hemangioma A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)	2	1	0
Cancer of Skin [description not available]	2	1	0
Skin Neoplasms Tumors or cancer of the SKIN.	2	1	0
Carcinoma, Anaplastic [description not available]	1.95	1	0
Experimental Neoplasms [description not available]	2.65	3	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	1.95	1	0
Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)	1.95	1	0
Malignant Melanoma [description not available]	1.95	1	0
Sarcoma 180 An experimental sarcoma of mice.	1.95	1	0
Sarcoma 37 An experimental sarcoma of mice.	1.95	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.95	1	0
Benign Neoplasms [description not available]	1.95	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1.95	1	0
Cancer of Ovary [description not available]	1.98	1	0
Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)	1.98	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1.98	1	0
Cancer of Salivary Gland [description not available]	1.97	1	0
Salivary Gland Neoplasms Tumors or cancer of the SALIVARY GLANDS.	1.97	1	0
Carcinoma, Colloid [description not available]	1.97	1	0
Cancer of Stomach [description not available]	2.37	2	0
Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)	1.97	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.37	2	0

chemdatabank.com